WO1999053949A2 - Combination of antigen pulsed apcs and interleukin 12 for tumor and viral therapy - Google Patents
Combination of antigen pulsed apcs and interleukin 12 for tumor and viral therapy Download PDFInfo
- Publication number
- WO1999053949A2 WO1999053949A2 PCT/US1999/008889 US9908889W WO9953949A2 WO 1999053949 A2 WO1999053949 A2 WO 1999053949A2 US 9908889 W US9908889 W US 9908889W WO 9953949 A2 WO9953949 A2 WO 9953949A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- cells
- peptide
- tumor
- pulsed
- Prior art date
Links
- 108091007433 antigens Proteins 0.000 title claims description 115
- 239000000427 antigen Substances 0.000 title claims description 111
- 102000036639 antigens Human genes 0.000 title claims description 111
- 108010065805 Interleukin-12 Proteins 0.000 title claims description 69
- 102000013462 Interleukin-12 Human genes 0.000 title claims description 69
- 206010028980 Neoplasm Diseases 0.000 title abstract description 182
- 238000002560 therapeutic procedure Methods 0.000 title description 14
- 230000003612 virological effect Effects 0.000 title description 4
- 229940117681 interleukin-12 Drugs 0.000 title description 3
- 101150020229 Apcs gene Proteins 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 100
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 49
- 230000001461 cytolytic effect Effects 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 230000001939 inductive effect Effects 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 214
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 96
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 95
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 62
- 201000001441 melanoma Diseases 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 41
- 210000004443 dendritic cell Anatomy 0.000 claims description 39
- 241000282414 Homo sapiens Species 0.000 claims description 31
- 102000016200 MART-1 Antigen Human genes 0.000 claims description 25
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 25
- 210000004989 spleen cell Anatomy 0.000 claims description 18
- 230000028993 immune response Effects 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 15
- 102000003425 Tyrosinase Human genes 0.000 claims description 12
- 108060008724 Tyrosinase Proteins 0.000 claims description 12
- 239000002158 endotoxin Substances 0.000 claims description 12
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 10
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 10
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 10
- 238000011287 therapeutic dose Methods 0.000 claims description 8
- 210000002950 fibroblast Anatomy 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 42
- 238000011282 treatment Methods 0.000 abstract description 37
- 201000011510 cancer Diseases 0.000 abstract description 19
- 206010027480 Metastatic malignant melanoma Diseases 0.000 abstract description 9
- 208000021039 metastatic melanoma Diseases 0.000 abstract description 9
- 230000036210 malignancy Effects 0.000 abstract description 6
- 230000001976 improved effect Effects 0.000 abstract description 4
- 230000002939 deleterious effect Effects 0.000 abstract description 3
- 239000012678 infectious agent Substances 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 173
- 238000002649 immunization Methods 0.000 description 103
- 230000003053 immunization Effects 0.000 description 103
- 241000699670 Mus sp. Species 0.000 description 60
- 108090000623 proteins and genes Proteins 0.000 description 50
- 230000004044 response Effects 0.000 description 43
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 238000002347 injection Methods 0.000 description 30
- 239000007924 injection Substances 0.000 description 30
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 29
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 28
- 239000013615 primer Substances 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 27
- 150000001413 amino acids Chemical class 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 25
- 210000004881 tumor cell Anatomy 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 238000000338 in vitro Methods 0.000 description 23
- 238000001727 in vivo Methods 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 238000011765 DBA/2 mouse Methods 0.000 description 21
- 108010074328 Interferon-gamma Proteins 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 20
- 238000003556 assay Methods 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 210000004988 splenocyte Anatomy 0.000 description 20
- 230000001988 toxicity Effects 0.000 description 20
- 231100000419 toxicity Toxicity 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 102100037850 Interferon gamma Human genes 0.000 description 19
- 101100088246 Mus musculus Rpl13a gene Proteins 0.000 description 19
- 239000012071 phase Substances 0.000 description 19
- 238000002255 vaccination Methods 0.000 description 19
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 17
- 239000011886 peripheral blood Substances 0.000 description 17
- 210000005259 peripheral blood Anatomy 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 16
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 239000011347 resin Substances 0.000 description 14
- 229920005989 resin Polymers 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
- 238000013459 approach Methods 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 208000037821 progressive disease Diseases 0.000 description 13
- 229910001868 water Inorganic materials 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000009089 cytolysis Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 239000008215 water for injection Substances 0.000 description 11
- 230000003442 weekly effect Effects 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 241001529936 Murinae Species 0.000 description 10
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 10
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 230000002101 lytic effect Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 229910004373 HOAc Inorganic materials 0.000 description 8
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 8
- 239000011651 chromium Substances 0.000 description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 7
- PQGCYSRGXCORLN-UHFFFAOYSA-N 2-[[2-[2-[[2-[[1-[2-[[2-[[2-[(2-amino-3-phenylpropanoyl)amino]-4-methylpentanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoylamino]-4-methylpentanoyl]amino]-3-methylbutan Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NCC(=O)N1C(CCC1)C(=O)NC(CCCN=C(N)N)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(N)CC1=CC=CC=C1 PQGCYSRGXCORLN-UHFFFAOYSA-N 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 201000006512 mast cell neoplasm Diseases 0.000 description 7
- 208000006971 mastocytoma Diseases 0.000 description 7
- 210000005087 mononuclear cell Anatomy 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- -1 coatings Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000000139 costimulatory effect Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 229960003767 alanine Drugs 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 229960004799 tryptophan Drugs 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 239000012646 vaccine adjuvant Substances 0.000 description 5
- 229940124931 vaccine adjuvant Drugs 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241001289721 Lethe Species 0.000 description 4
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 4
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 4
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000003092 anti-cytokine Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011285 therapeutic regimen Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 159000000021 acetate salts Chemical class 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 238000011254 conventional chemotherapy Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000004940 costimulation Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 201000005488 Capillary Leak Syndrome Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 101000972324 Cynodon dactylon Leaf protein Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920001367 Merrifield resin Polymers 0.000 description 2
- 206010059282 Metastases to central nervous system Diseases 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000031932 Systemic capillary leak syndrome Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000021017 Weight Gain Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011551 log transformation method Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000012737 microarray-based gene expression Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000011255 standard chemotherapy Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 1
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- HSQIYOPBCOPMSS-ZETCQYMHSA-N (2s)-5-(diaminomethylideneamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCN=C(N)N HSQIYOPBCOPMSS-ZETCQYMHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 240000007241 Agrostis stolonifera Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 1
- 108010014597 HLA-B44 Antigen Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 101100323015 Mus musculus Alk gene Proteins 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- NFVNYBJCJGKVQK-ZDUSSCGKSA-N N-[(Tert-butoxy)carbonyl]-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CNC2=C1 NFVNYBJCJGKVQK-ZDUSSCGKSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100024550 Sphingomyelin phosphodiesterase 2 Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- TTZLKXKJIMOHHG-UHFFFAOYSA-M benzyl-decyl-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 TTZLKXKJIMOHHG-UHFFFAOYSA-M 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011259 co-electroporation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229940040731 human interleukin-12 Drugs 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000004046 hyporesponsiveness Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- FKADDOYBRRMBPP-UHFFFAOYSA-N lacto-N-fucopentaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)OC1CO FKADDOYBRRMBPP-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 108010071421 milk fat globule Proteins 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108040005466 neutral sphingomyelin phosphodiesterase activity proteins Proteins 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates generally to the fields of immunotherapy, oncology and infectious disease control. More particularly, it concerns novel methods of treating infectious diseases and cancers, in particular melanomas, with a combinatorial adjuvant or adjuvants in such a manner that an unexpectedly strong immune response directed against the diseases or melanomas is induced without the deleterious side effects that have been previously observed with standard chemotherapy.
- Melanoma is a cancer of the pigmented cell of the skin, the melanocyte.
- Patients with metastatic (Stage IV) malignant melanoma have a median survival of approximately one year (Balch et al, 1993; Koh, 1991).
- Current standard treatment consists of combination chemotherapy with agents such as cisplatin, DTIC, and BCNU, with or without cytokines such as interleukin-2 (IL-2) or interferon- ⁇ (IFN- ⁇ ) (Balch et al, 1993; Koh, 1991; Legha and Buzaid, 1993).
- IL-2 interleukin-2
- IFN- ⁇ interferon- ⁇
- Vaccinations with irradiated tumor cells, with or without adjuvants have generated response rates of 10-20% (Berd et al, 1990).
- Non-specific immune potentiators such as Bacillus Calmette-Guerin (BCG) also have given low but detectable response rates (Eilber et al, 1976).
- BCG Bacillus Calmette-Guerin
- Treatment of patients with metastatic renal cell carcinoma with the T cell growth factor IL-2 has resulted in response rates of 15-20%, with several percent of patients experiencing a significant long-term survival (Hawkins, 1996).
- the addition of IL-2 to standard chemotherapy for metastatic melanoma may result in increased response rates (Eilber et al, 1976).
- initiation of an immune response is triggered by peptide/MHC complexes expressed by host antigen-presenting cells (APC), and additionally requires multiple cofactors provided by APC.
- APC host antigen-presenting cells
- Several cell types appear to be capable of serving as "professional" APC, including dendritic cells (DC), activated B cells, and activated macrophages.
- DC dendritic cells
- activated B cells activated macrophages.
- CTL induced by APC interactions are thought to migrate throughout the host, recognize the same MHC/peptide complex on the tumor cells, and are triggered to kill them.
- This antigen-specific cytolysis is mediated largely via induction of apoptosis. It is hypothesized that one or several steps along this pathway of T cell activation and target cell recognition may be defective in tumor-bearing individuals.
- MAGE-1 was the first human tumor antigen gene to be cloned and characterized (Van der Bruggen et al, 1991). It is expressed by several melanoma cell lines but not by any adult tissues except the testis. Therefore, it falls into category 6 listed above, being a normal gene that is abnormally expressed. MAGE-1 belongs to a family of at least 12 related genes, many of which also are expressed in various tumor cell types (De Plaen et al, 1994). One of these, MAGE-3, has been found to be expressed in approximately two-thirds of all melanoma samples tested.
- HLA-A2 is the most frequently expressed HLA allele in humans, present in about 50% of individuals.
- Melan-A is expressed by nearly all melanoma cell lines tested (Coulie et al. , 1994), as well as in normal melanocytes. It therefore falls into category 2 above, encoding a melanocyte differentiation antigen.
- a peptide encoded by Melan-A has been defined that binds to HLA-A2.
- T lymphocyte activation and differentiation have indicated several key costimulatory factors provided by APC that are vital for the optimal generation of CD8 + CTL.
- stimulation of T cells via the T cell receptor for antigen (TCR) in the absence of additional costimulatory factors has been shown to induce not activation, but rather an unresponsive state termed clonal anergy (Schwartz, 1990; Tan et al, 1993).
- TCR T cell receptor for antigen
- participation of costimulator molecules is an essential component to initiating productive T cell differentiation.
- the specific cofactors present during and immediately after initial T-cell encounter with antigen determine the functional phenotype of the cells that emerge.
- Tel cells For CD8 T cells, the principal functional phenotypes fall into two subsets designated Tel and Tc2 (Sad et al, 1995). Tel cells produce high levels of IFN- ⁇ and TNF and have high lytic activity, whereas Tc2 cells produce IL-4 and IL-5 and are poorly lytic (Cronin et al, 1995). It has been suggested that a Tel -type response might be superior at mediating tumor rejection.
- B7-family of costimulator molecules comprised of B7-1 and B7-2, appears to be important for instructing developing T cells to produce IL-2, and for preventing induction of T cell unresponsiveness or anergy (Linsley et al, 1991; Harding et al, 1992; Gimmi et al, 1993).
- B7-1/B7-2 interact with two counter-receptors, designated CD28 and CTLA4, on the surface of T lymphocytes. Provision of B7 during the activation of naive T cells is the trigger that gets the initial response going. At that point, the particular exogenous cytokines present determine the functional phenotype of the resulting activated effector cells.
- IL-12 appears to induce a high IFN- ⁇ -producing Tel phenotype, whereas IL-4 favors development of Tc2 cells (Sad et al, 1995). These characteristics parallel those of CD4 helper T lymphocytes (Fitch et al, 1993). Provision of both B7 and IL-12 allows generation of potent tumor antigen-specific CTL in vitro (Gajewski et al, 1995). In several murine models in vivo, transfection of immunogenic tumors to express B7 has resulted in CD8 T cell-dependent rejection by syngeneic mice (Townsend and Allison, 1993, Chen et al, 1994).
- IL-12 also can facilitate the regression of murine tumors in a T cell-dependent fashion (Brunda et al, 1993). Blockade of host B7 or IL-12 in vivo prevents the rejection of otherwise very immunogenic tumors (Gajewski et al, 1996; Fallarino et al, 1996), indicating that these two factors are normally employed by the immune response mediating tumor rejection.
- the present invention provides methods of overcoming shortcomings of the prior art by providing improved methods of treating diseases and infections that are unexpectedly effective in inducing immune responses directed against diseases and infections.
- the invention relates to treating melanomas, such as metatstatic melanomas, and viral infections.
- melanomas such as metatstatic melanomas
- the inventors have discovered that administration of the adjuvants in the described manner are far more effective than would have been predicted based on the prior art or when the adjuvants are administered either alone or in a different combination or order.
- the invention provides the further advantage of reducing deleterious side effects that have been previously associated with cancer therapies.
- references to "a cell”, “a peptide” and “an adjuvant” include mixtures of cells, one or more peptides and a plurality of adjuvants of the type described; and reference to “IL-12” includes different species of such IL-12, for example, recombinant human IL-12, and so forth.
- a recombinant peptide As used herein, the term "a recombinant peptide”, unless otherwise expressly stated, is used to succinctly refer to a recombinant peptide which is derived from an antigen that can be recognized by T-lymphocytes. "Recombinant peptides” are generally peptide molecules that may be provided to cells (or animals) by the hand of man. The term “recombinant” peptide does not generally extend to amino acid sequence, peptides and proteins that may have been moved by a process of nature such that they have "recombined” in a sequence or order different to the parent cell or organism from which they were derived without intervention by man.
- the invention provides a method of inducing a mammalian immune response comprising: providing a composition comprising IL-12 and antigen-presenting cells pulsed with peptide and administering the composition to a mammal in an amount effective to induce an immune response.
- the composition, or adjuvant comprises peptide-pulsed, or loaded, antigen-presenting cells (APCs) and IL-12.
- the invention further provides that the APCs comprise autologous cells and in some illustrative embodiments the antigen-presenting cells may comprise B cells activated by lipopolysaccharide, whole spleen cells, dendritic cells, fibroblasts or non-fractionated peripheral blood mononuclear cells (PMBC).
- PMBC peripheral blood mononuclear cells
- the APCs are pulsed, or loaded, with antigenic peptide or recombinant peptide derived from at least one antigen.
- the peptide comprises an antigenic fragment capable of inducing an immune response that is characterized by the production of cytolytic T lymphocytes (cytolytic T cells or CTLs) which are directed against a malignancy or infection by a mammal.
- the peptide comprises one or more fragments of an antigen binding to class I MHC or class II MHC molecules (see Tables 1 and 2 for lists of exemplary tumor antigens). It is understood that the antigens listed in Tables 1 and 2 are provided for illustrative purposes and the skilled artisan will recognize that the described invention is not limited to these illustrative antigens.
- the peptides comprise one or more fragments of one or more antigens expressed by melanoma tumors or other cancers, or infectious agents such as viruses, bacteria, parasites and the like.
- the peptide comprises MAGE-1, MAGE-3, Melan-A, PI 98, PI A, gplOO or tyrosinase.
- MAGE-1, MAGE-3, Melan-A, PI 98, PI A, gplOO or tyrosinase MAGE-1, MAGE-3, Melan-A, PI 98, PI A, gplOO or tyrosinase.
- peptides comprising one or more fragments of other antigens may be useful in the invention and that the invention is not limited to the exemplary peptides and antigens which are described herein.
- APCs may be pulsed with any effective concentration of peptide.
- the APCs comprise cells pulsed with about 0.1 ⁇ M - ImM peptide.
- the APCs comprise cells pulsed with about l ⁇ M -lOO ⁇ M peptide, with a further preferred embodiment with about lO ⁇ M -50 ⁇ M.
- the malignancy comprises a melanoma or other cancer, such as cancer of the prostate, ovary, kidney, lung, brain, breast, colon, bone, skin, testes or uterus
- the virus comprises a retrovirus, adenovirus, vaccinia virus, herpesvirus, adeno-associated virus, lentivirus, human immunodeficiency virus (HIV), or an arbovirus (arthropod-borne virus) (comprehensive lists and descriptions of arboviruses are provided in Entomology in Human and Animal Health. 7th ed., 1979 and The Biology of Disease Vectors. University Press Colorado, 1996, both of which are incorporated herein by reference).
- the infection comprises a bacterial or parasitic infection.
- Mammals include, but are not limited to, equines, cattle, felines, canines, rats, mice and humans.
- the invention provides a method of inducing a mammalian immune response, wherein the peptide-pulsed APCs are administered to a mammal in need thereof, in a single therapeutic dose in combination with a single therapeutic dose of IL-12 followed by multiple therapeutic doses of IL-12.
- Dosages may be any that induce an immune response.
- the amount of APCs administered comprises 1x10 - 1x10 per dose. In exemplary preferred embodiments the amount of APCs administered comprises about 1x10 per dose.
- the amount of IL-12 administered comprises Ing/kg-lOOOng/kg. In certain preferred exemplary embodiments the amount of IL-12 administered comprises 30-50ng/kg per dose.
- the preferred dosage should be individualized to the patient following good laboratory practices and standard medical practices.
- the invention provides a method of treating a patient with a malignancy or infection comprising administering an adjuvant or composition comprising peptide-pulsed antigen-presenting cells and IL-12.
- the invention provides a composition using tumor antigen peptide pulsed autologous PBMC with and without rhIL-12 to produce an immune response in humans.
- the tumor antigen peptide is Mage3 or MelanA.
- rhIL-12 is provided in addition to the Mage3 or MelanA.
- FIG. 1 Expression of surface markers by the various APCs used in this study. Splenic
- DC sDC
- unfractionated PBMC unfractionated B cells
- unfractionated splenocytes were prepared from naive DBA 2 mice as described in Example 1. The cells were then stained with the indicated FITC-conjugated mAbs and analyzed by flow cytometry. The data are representative of at least two separate replicates.
- FIG. 2 Production of TNF by CTL PI 98.6 clone stimulated with sDC pulsed with various doses of PI 98 tumor peptide. sDC were pulsed with the indicated concentrations of
- PI 98 peptide washed, and co-cultured with (solid symbols) or without (open symbols) the PI 98- specific CTL clone PI 98.6 for 24 hours.
- the TNF content of the supernatant was evaluated by determining its toxicity on WEHI-164 cells.
- FIG. 3 Scheme of immunization with P198-peptide loaded APCs.
- DBA/2 mice (usually 5 per group) were injected weekly for three consecutive weeks with various peptide-loaded APCs.
- rmIL-12 also was administered in some studies, and was injected along with peptide-pulsed APC on the day of each immunization on day 0, and again on days 1 and 2 as shown.
- Two weeks following the last immunization, spleen cells or PBMC were restimulated with the appropriate tumor cells and the specific cytolytic activity was determined after 6-7 days of culture.
- FIG. 4 Proportion of mice with specific CTL activity after immunization with PI 98 peptide-pulsed sDC.
- DBA/2 mice (5 group) were immunized weekly for three consecutive weeks with 5 x IO 5 P198-pulsed sDC in DPBS either i.v, i.p, or divided between both hind footpads (f.p.).
- an MLTC was performed with PI 98 cells (open bars), or P198.B7-1 cells (filled bars) as stimulators. Cytolytic activity was analyzed at day 6 against PI 98 or P511 in the presence of unlabeled P511 as a cold target.
- mice received sDC alone or PBS, neither of which induced detectable CTL. Mice were considered to be positive if the specific lysis at E:T ratio 100:1 was greater than 25 and if the difference between lysis of PI 98 and P511 was greater than 15. Similar results were observed in two studies.
- FIG. 5A and FIG. 5B Immunization of naive mice with various APCs pulsed with
- P198 peptide in combination with rmIL-12 Naive DBA/2 mice were immunized with P198 peptide-pulsed sDC, splenocytes, or PBMC with (FIG. 5 A) or without (FIG. 5B) rmIL-12 as described in Example and in FIG 3.
- Peptide (l ⁇ M) peptide was used for pulsing of each APC type.
- sDC 5 x 10 5
- PBMC peripheral blood mononuclear cells
- PBMC peripheral blood mononuclear cell
- FIG. 6 Production of IFN- ⁇ by CTL P198.6 clone stimulated with different types of APCs pulsed with the PI 98 peptide.
- DBA-derived sDC, unfractionated splenocytes, resting B cells, LPS-activated spleen cells, PBMC, or P511 tumor cells were pulsed with varying concentrations of the PI 98 peptide, washed, then co-cultured with the CTL PI 98.6 clone for 48 hours.
- the IFN- ⁇ content of the supernatants was evaluated using a specific ELISA.
- FIG. 7 Lysis of PI 98 target cells by CTL from mice immunized with P198-peptide-pulsed APCs plus rmIL-12.
- DBA/2 mice were injected weekly for 3 weeks with P198 peptide-pulsed sDC (5 x IO 5 ), B cells (0.5-20 x 10°), spleen cells (0.5-20 x IO 6 ), or PBMC (0.5-2 x IO 6 ) along with rmIL-12 as described previously.
- the sDC were pulsed with 1 ⁇ M peptide, whereas the other cells were pulsed with 10 ⁇ M peptide.
- PBMC peripheral blood mononuclear cells
- FIG. 8A-8D CTL activity obtained from individual DBA/2 mice immunized with PI A peptide-pulsed PBMC with or without rmIL-12.
- Naive DBA/2 mice (5 per group) were immunized weekly for 3 weeks with 2 x 10 irradiated PBMC pulsed with PI A peptide (10 ⁇ M) alone (FIG. 8A) or in combination with rmIL-12 (FIG. 8B).
- Control mice were injected with non-pulsed PBMC plus rmIL-12 (FIG. 8C) or with DPBS (FIG. 8D).
- PBMC Two weeks following the last immunization, PBMC were isolated and stimulated with LI210.P1A.B7-1 cells, and cytolytic activity was assessed at day 6 against P511 and PI 204 target cells.
- FIG. 9 Protection against living Pl.HTR tumor challenge in mice immunized with PI A- loaded PBMC plus rmIL-12.
- Naive DBA/2 mice (5 per group) were immunized weekly for 3 weeks with DPBS (closed triangles), PBMC plus rmIL-12 (open triangles), PBMC loaded with
- mice were challenged s.c. in the left flank with 1 x 10 living PI .HTR tumor cells. Bidimensional measurements were recorded at the indicated times. Similar results were obtained in at least two studies.
- FIG. 10 Vaccination of melanoma patients with refractory metastatic disease was demonstrated using tumor antigen peptide-pulsed autologous PBMC without rhIL-12.
- FIG. 11 Vaccination of melanoma patients with refractory metastatic disease was demonstrated using tumor antigen peptide-pulsed autologous PBMC with 30ng/kg rhIL-12.
- FIG. 12 Vaccination of melanoma patients with refractory metastatic disease was demonstrated using tumor antigen peptide-pulsed autologous PBMC with 30ng/kg rhIL-12. Generation of peptide-specific, IFN- ⁇ -producing CD8 + T cells was detected after 1 to 3 immunizations with Mage3 (lO ⁇ m) or MelanA (50 ⁇ m).
- the invention discloses novel methods of using a vaccine adjuvant which specifically induces antigen-specific immune stimulation against an antigen derived from a tumor or infectious agent.
- Mammalian blood cells that are pulsed by this innovative method have been demonstrated to induce specific cytolytic T lymphocyte (CTL) production and protect from tumorgensis.
- CTL cytolytic T lymphocyte
- the method admixes the tumor or disease antigen with autologous peripherial blood cells which are then irradiated and injected back into the animal or patient.
- the injection is co-administered with IL-12 which helps to stimulate the immune system to promote an anti-neoplastic or anti-disease response in the animal or patient.
- this method has been applied to mice using the mastocytoma tumor antigens PI 98 and PI A, and to humans using the melanoma antigens MAGE-3 and Melan-A.
- the use of autologous peripherial blood cells which can be readily harvested and rapidly prepared in a few hours, provides a significant improvement over other therapies which require lengthy purification and culturing techniques of several weeks thus causing a critical delay in treatment.
- the combination of autologous peripherial blood cells with antigen and IL-12 yields an unexpectedly high inhibition of tumor growth such that tumor regression or even disappearance occurs, and extraordinarily, living tumor challenges may not result in tumor occurrence.
- CTLs are involved directly in the body's defense against any infection and are well- known to kill virus-infected cells. Further, as CTLs recognize foreign antigens in the context of class I MHC molecules, the invention is not restricted to the treatment of cancers but can be useful in the treatment of infectious diseases, especially viral diseases, for which an antigenic peptide that binds to class I MHC molecules can be admixed with autologous peripheral blood cells. It is not necessary for the practice of the invention that the antigenic peptide be provided in a purified or isolated state.
- the methods of the invention will be useful in the treatment of infectious, viral or parasitic diseases that are resistant to other therapies, such as arboviruses or malaria, or for which effective vaccines are not known, such as human immunodeficiency virus (HIV) and herpes viruses and certain arboviruses.
- HIV human immunodeficiency virus
- this invention can be useful surveillance therapies designed to prevent the recurrence of disease, such as tumor regeneration, and in preventative therapies such as vaccinations against viral or parasitic diseases, such as encephalitis or malaria.
- this invention provides novel methodology and immunization protocols which are surprisingly more effective in the generation of CTLs than conventional approaches and have the additional improvement of requiring less time to prepare the vaccine adjuvant or adjuvants compared to other therapies.
- a further advantage of this invention is that few, if any, deleteriores side effects occur in the animal or patient through the administration of the vaccine adjuvant.
- CTL in the human system activated B cells or dendritic cells were isolated from a normal individual expressing HLA-A2. These cells were incubated with a peptide derived from MAGE- 3 predicted to bind HLA-A2, and were used to stimulate CD8 + T cells from the same individual. Only if IL-12 was included during the initial stimulation were specific CTL induced after expansion which could lyse melanoma cell lines expressing MAGE-3 (Van der Bruggen et al. , 1994). Inasmuch as HLA-A2 is the most frequently expressed HLA allele and MAGE-3 is the most frequently expressed MAGE gene among melanoma samples examined, this peptide/HLA combination is suggested for human immunizations. A peptide derived from another tumor antigen, Melan A, also has been identified that binds to HCA-A2 and can be recognized by CTLs.
- Abs antibodies; Ags, antigens; EGF, epidermal growth factor; GI, gastrointestinal; GICA, gastrointestinal-associated antigen; GP, glycoprotein; GY, gynecological; HMFG, human milk fat globule; Kd, kilodaltons; Mabs, monoclonal antibodies; M r , molecular weight; NS, not specified; PLAP, placental alkaline phosphatase; TAG, tumor-associated glycoprotein; CEA, carcinoembryonic antigen.
- GICA the CA 19-9 Ag
- GICA is sialosylfucosyllactotetraosylceramide, also termed sialylated Lewis pentaglycosyl ceramide or siaiyated lacto-N-fucopentaose II
- p97 Ags are believed to be chondroitin sulphate proteoglycan
- antigens reactive with Mab 9-2-27 are believed to be sialylated glycoproteins associated with chondroitin sulphate proteoglycan
- GY can include cancers of the cervix, endocervix, endometrium, fallopian tube, ovary, vagina or mixed Mullerian tumor
- GI can include cancers of the liver, small intestine, spleen, pancreas, stomach and oesophagus.
- P815 is a mastocytoma and not a melanoma cell line, it is likely that the principles of tumor antigen immunity defined with this model system are generally applicable to other tumor types.
- the advantages of the system are multiple. Five tumor antigens expressed by P815 have been identified according to recognition by CTL clones (Brichard et al, 1995), and the gene PI A encoding two of these antigens has been cloned and characterized (Van den Eynde et al, 1991).
- the genomic sequence of PI A in P815 tumor cells is identical to that in normal mouse cells, indicating that it is a normal gene that is abnormally expressed.
- mice Groups of 6-10 female DBA/2 mice were treated for each condition examined.
- naive (non-tumor-bearing) mice were immunized.
- the studies were performed by pulsing different APC with PI 98 peptide at 1 ⁇ g/ml. These procedures were performed next using PI A peptide in an identical fashion, with peptide-specific CTL activity from peripheral blood measured as a surrogate readout.
- Cytokine production particularly IFN- ⁇ and TNF- ⁇ , were assessed in parallel studies following restimulation of effector T cells with peptide-pulsed syngeneic APCs or antigen-expressing tumor cell lines.
- the optimal dose of peptide for immunization was determined.
- Whole syngeneic splenocytes are pulsed with 10 or 1 ⁇ g/ml of PI A peptide, washed, irradiated (2,000 rad), and injected into the mice. The optimal number of injections was assessed.
- One advantage of using peripheral blood as a source of T lymphocytes to assay is that the mice do not need to be sacrificed in order to measure CTL activity. In this way, levels of CTL activity were examined at weekly intervals prior to each immunization. This approach is analogous to that which is used for patient studies.
- a general goal of the pre-clinical model was to construct a specific procedure that was then transferred to patient use. The optimal location of immunization is not yet known. Pulsed APC were injected subcutaneously, intradermally, intravenously, and intraperitoneally, and CTL activity were measured as before.
- lymphoid cell populations can function for immunization, it was not clear whether the few DC present in the mixture were actually responsible for the effect. Both spleen cells and PBMC contain a population of DC precursors. Nonetheless, the inventors reasoned that many cell types can serve as APC for immunization, provided IL-12 is administered as well. The hypothesis was tested rigorously by comparing pulsed purified resting B cells, activated B cells, DC, and fibroblasts. If each of these class I MHC + APC populations induced specific CTL when pulsed with peptide and co-injected with IL-12, then the conclusion that provision of IL-12 makes the nature of the APC irrelevant could be made.
- PBMC peripheral blood mononuclear cells
- Peripheral blood macrophages as a source of APC have been cultured from the blood of melanoma patients, pulsed with a peptide derived from MAGE-1, and injected back into the patients subcutaneously and intravenously (Mukherji et al, 1995), No major toxicities were observed. Biopsy of the immunization sites revealed the presence of MAGE-1 -specific CTL, suggesting that a specific immune response was initiated. Based on the success in the mouse model using non-fractionated PBMC as a source of APC, the inventors reasoned that it may not be necessary to carry out a procedure for in vitro expansion of macrophages or DC to obtain a successful immunization. The use of non-fractionated PBMC would simplify considerably the preparation of the vaccine, and avoid potential sources of toxicity.
- rhIL-12 human IL-12
- Toxicities included transient cytopenias (nadirs occurring 2-5 days after treatment), reversible increases of transaminases and bilirubin, transient hyperglycemia, stomatitis, and capillary leak syndrome.
- a second Phase I clinical study of rhIL-12 was conducted, employing subcutaneous administration 3 times a wk for 2 wk, followed by one wk off. Patients were treated at dose levels of 3, 10, 30, 100, and 300 ng/kg/day. The maximally tolerated dose was not achieved as the trial was suspended after a clinical hold was placed on the Phase II renal cell carcinoma studies described below.
- rhIL-12 a third Phase I study of rhIL-12 was completed. Cohorts of 6 patients were treated by subcutaneous injection 3 times per wk for 2 wk followed by a 9 day rest period, at doses of 30, 100, and 300 ng/kg/day. There were no major toxicities, and 3 patients were then treated at a 500 ng/kg/day dose. Two renal cell carcinoma patients appeared to have a minor response. This dose range and schedule of rhIL-12 appear to be well tolerated in patients with advanced malignancies.
- Peripheral blood was collected and fractionated by density centrifugation to isolate PBMC as a source of APC.
- Cells were incubated with the appropriate MAGE-3 or Melan-A peptide, washed, resuspended in PBS, and lethally irradiated.
- Pulsed cells 50-100 x 10 ) were injected subcutaneously at 2 sites, near lymph node locations but not adjacent to a tumor mass. The subcutaneous route was preferred for the reasons of safety, efficacy in the preclinical model, and the goal of targeting the vaccine to a draining lymph node.
- Eligible patients were assigned to the respective cohorts as they came, whether being immunized with MAGE-3 or Melan-A peptide.
- Three to six patients were treated with peptide- pulsed PBMC alone, using either MAGE-3 or Melan-A peptide as indicated.
- rhIL-12 was administered subcutaneously near one of the immunization sites on days 1, 3, and 5.
- the dose of rhIL-12 was escalated in groups of 3-6 patients each, to determine an optimal dose with respect to safety and successful immunization.
- the dosing schedule was based on the most recent phase I data. Reimmunization was performed at 3 wk intervals, with rhIL-12 administration on days 1, 3, and 5 of each cycle.
- peripheral blood was collected to assay for peptide-specific CTL activity and production of IFN- ⁇ and TNF- . Injection sites also were examined for local inflammation indicative of a delayed-type hypersensitivity reaction. Clinical response was assessed as a secondary outcome.
- tumor antigen-specific immunization approach is the ability to measure a specific immune response independently of an effect on tumor regression which has not been possible with more generic immunotherapies, such as injection of recombinant IL-2, because the antigens expressed by the patient's tumor are not normally analyzed. In addition, any successfully generated response might be directed against antigens that are not yet characterized and therefore would go undetected.
- a first step to improving upon immunotherapy of cancer is to determine whether or not successful immunization has occurred; only then can vaccination be improved upon in order to determine its true potential in cancer therapy.
- the second assay measures MAGE-3- or MelanA-specific cytolytic activity from the cryopreserved PBMC which is assessed by re-stimulating the T lymphocytes with peptide-pulsed APC, expanding the responding cells with IL-2, and measuring lysis of chromium-labeled target cells expressing the correct MHC molecules and pulsed with MAGE-3 or MelanA peptide.
- Controls include non-pulsed targets and the NK-sensitive target K562. Cold competition is performed with non-radiolabelled K562 cells to eliminate non-specific NK activity.
- the third readout is a combination of the first and the second approaches. Because a
- Thl/Tc2 phenotype might be predictive of anti-tumor efficacy
- the effector cells generated upon expansion of specific T cells in the second method are stimulated for 24 hours with peptide- pulsed APC, and the supematants are assayed for the presence of IFN- ⁇ and TNF- ⁇ . Even if the serum levels are undetectable, cytokine production by the antigen-specific T cells should be easily measurable.
- a vaccination study of patients with refractory metastatic disease was conducted using tumor antigen peptide pulsed autologous PBMC with and without rhIL-12.
- Mage3 and MelanA generation of peptide-specific, IFN- ⁇ -producing CD8 + T cells was detected after 1 to 3 immunizations as shown in FIG. 10, FIG. 1 1. and FIG. 12.
- the therapeutic regimen described herein can be utilized with any antigenic peptide that binds to class I MHC molecules.
- MAGE-3 and Melan A peptides described biological functional equivalents are described.
- modification and changes may be made in the structure of the recombinant peptide and still obtain a molecule having like or otherwise desirable characteristics.
- certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of T cell antigen receptors or binding sites on HLA molecules of melanoma cells.
- Biologically functional equivalent peptides are thus defined herein as those peptides in which certain, not most or all, of the amino acids may be substituted. In particular, where small peptides are concerned, less amino acids may be changed. Of course, a plurality of distinct proteins/peptides with different substitutions may easily be made and used in accordance with the invention.
- residues may not generally be exchanged.
- Amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like.
- An analysis of the size, shape and type of the amino acid side-chain substituents reveals that arginine, lysine and histidine are all positively charged residues; that alanine, glycine and serine are all a similar size; and that phenylalanine, tryptophan and tyrosine all have a generally similar shape.
- arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine; are defined herein as biologically functional equivalents.
- hydropathic index of amino acids may be considered.
- Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).
- hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, 1982, incorporated herein by reference). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within ⁇ 2 is preferred, those which are within ⁇ 1 are particularly preferred, and those within ⁇ 0.5 are even more particularly preferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biological functional equivalent protein or peptide thereby created is intended for use in immunological embodiments, as in the present case.
- hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 ⁇ 1); glutamate (+3.0 ⁇ 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 ⁇ 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).
- codons that encode the same amino acid such as the six codons for arginine or serine, and also refers to codons that encode biologically equivalent amino acids (see Codon Table, above).
- amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned.
- the addition of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, / ' . e. , introns, which are known to occur within genes.
- a therapeutic regimen is described herein; however, the treatment with IL-12 may precede or follow administration of peptide-pulsed APC by intervals ranging from seconds to hours to days to even weeks.
- peptide-pulsed APC and IL-12 are administered separately to the patient, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the combination of the two would still be able to exert an advantageously combined effect on the recipient.
- peptide-pulsed APC is "A” and IL-12 is "B": A/B/B B/A/A A/A/B
- both agents are delivered to a patient in a combined amount effective to kill the tumor cells. These treatment cycles can be repeated multiple times, or delivered only once.
- 50 ⁇ M peptide is loaded onto APCs, 10x10 APCs are administered per injection and 30-50 ng/kg IL-12 is administered per injection.
- the amount of peptide loaded onto APCs may be as little as about 0.1 ⁇ m to as much as about ImM. It is understood that this range includes 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, etc.; 1, 2, 3, 4,
- the number of APCs per injection may also be varied from 1x10 -1x10 . It is understood that this range is inclusive of all doses between about 1x10 and 1x10 . Thus this range includes lxlO 6 , 2xl0 6 , 3xl0 6 , 4xl0 6 , 5x10 6 , 6xl0 6 , 7xl0 6 , 8xl0 6 , 9x10°, lxlO 7 , 2xl0 7 , 3xl0 7 , 4xl0 7 , 5xl0 7 , 6xl0 7 , 7xl0 7 , 8xl0 7 , 9xl0 7 , lxlO 8 , 2xl0 8 , 3xl0 8 , 4xl0 8 , 5xl0 8 , 6xl0 8 , 7xl0 8 , 8xl0 8 and 9xl0 8
- the amount of IL12 which can be administered ranges from 1 ng/kg - 1000 ng/kg per injection. It is understood that this range is inclusive of all doses between about 1 ng/kg and about 1000 ng/kg. Thus this range includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, etc.; 20, 21, 22, 23, etc.; 25, 26, 27, 28 etc.; 30, 31, 32, 33, etc.; 35, 36, 37, etc.; 40, 41, 42 etc.; 45, 46, 47, etc.; 50, 51, 52, 53, etc.; 60, 61, 62, etc.; 70, 71, 72, etc.; 80, 81, 82, etc.; 90, 91, 92, etc.; 100, 110, 120, etc.; 150, 160, 170, etc.; 200, 210, 220, etc.; 250, 260, 270 etc.; 300, 310, 320, 330, etc.; 350, 360, 370, etc.; 400, 410, 420, etc.
- Peptide-pulsed APC and IL-12 can be administered intravenously, intraarterially, intratumorally, parenterally or intraperitoneally.
- the preferred routes of administration are subcutaneous (SC); however, intravenous (IV), intrarterial, and intraperitoneal (IP) can be used.
- Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- a coating such as lecithin
- surfactants for example, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
- the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- either or both peptide-pulsed APC and IL-12 may also be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or enclosed in hard or soft shell gelatin capsule, or compressed into tablets, or incorporated directly with the food of the diet.
- the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- Such compositions and preparations should contain at least 0.1% of the active compound.
- the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of the unit.
- the amount of active compounds in such therapeutically useful compositions is such that a suitable dosage will be obtained.
- the tablets, troches, pills, capsules and the like may also contain the following: a binder, as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring.
- a binder as gum tragacanth, acacia, cornstarch, or gelatin
- excipients such as dicalcium phosphate
- a disintegrating agent such as corn starch, potato starch, alginic acid and the like
- a lubricant such as magnesium stearate
- a sweetening agent such as sucrose, lactose or saccharin may be added or a flavor
- tablets, pills, or capsules may be coated with shellac, sugar or both.
- a syrup of elixir may contain the active compounds sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor.
- any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
- the active compounds may be incorporated into sustained-release preparation and formulations. Screening and Monitoring Effectiveness of Therapy
- TUNEL terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labeling
- ELISAs enzyme linked immunosorbent assays
- Certain preferred immunoassays are the various types of ELISAs and radioimmunoassays (RIA) known in the art. Immunohistochemical detection using tissue sections is also particularly useful. However, it will be readily appreciated that detection is not limited to such techniques, and western blotting, dot blotting, ELISPOT, FACS analyses, and the like may also be used.
- an antibody against a cytokine such as IFG ⁇
- a cytokine such as IFG ⁇
- a composition containing the counterpart cytokine is added to the wells.
- the bound cytokine protein complex may be detected.
- Detection is generally achieved by the addition of an anti-cytokine or anti-tumor protein antibody that is linked to a detectable label.
- Detection may also be achieved by the addition of a first anti-cytokine or anti-tumor protein antibody, followed by a second antibody that has binding affinity for the first antibody, with the second antibody being linked to a detectable label.
- ELISAs have certain features in common, such as coating, incubating or binding, washing to remove non-specifically bound species, and detecting the bound immune complexes. These are described as follows:
- a plate with the primary antibody In coating a plate with the primary antibody, one will generally incubate the wells of the plate with a solution of the agent, either overnight or for a specified period of hours. The wells of the plate will then be washed to remove incompletely adsorbed material. Any remaining available surfaces of the wells are then "coated" with a nonspecific protein that is neutral with regard to binding to the biological components. These include bovine serum albumin (BSA), casein, and solutions of milk powder.
- BSA bovine serum albumin
- casein casein
- the coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of proteins onto the surface.
- the immobilizing surface is contacted with the second biological protein under conditions effective to allow protein complex formation. Detection of the complex then requires a labeled binding ligand or antibody.
- Under conditions effective to allow protein complex formation means that the conditions preferably include diluting the tumor antigen and cytolkine proteins, with solutions such as BSA, bovine gamma globulin (BGG) and phosphate buffered saline (PBS)/Tween. These added agents also tend to assist in the reduction of nonspecific background.
- the "suitable” conditions also mean that the incubation is at a temperature and for a period of time sufficient to allow effective binding. Incubation steps are typically from about 1 to 2 to 4 hours, at temperatures preferably on the order of 25° to 27°C, or may be overnight at about 4°C or so.
- the contacted surface is washed so as to remove non-complexed material.
- a preferred washing procedure includes washing with a solution such as PBS/Tween, or borate buffer. Following the formation of specific complexes between the test sample and the originally bound material, and subsequent washing, the occurrence of even minute amounts of bound complexes may be determined.
- a first or second antibody will preferably be provided that has an associated label to allow detection.
- the label will be an enzyme that will generate color development upon incubating with an appropriate chromogenic substrate.
- a urease, glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody for a period of time and under conditions that favor the development of immunocomplex formation (e.g., incubation for 2 hours at room temperature in a PBS-containing solution such as PBS-Tween).
- the amount of label is quantified, e.g., by incubation with a chromogenic substrate such as urea and bromocresol purple or 2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulfonic acid [ABTS] and H 2 O 2 , in the case of peroxidase as the enzyme label. Quantification is then achieved by measuring the degree of color generation, e.g., using a visible spectra spectrophotometer.
- a chromogenic substrate such as urea and bromocresol purple or 2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulfonic acid [ABTS] and H 2 O 2 , in the case of peroxidase as the enzyme label.
- Quantification is then achieved by measuring the degree of color generation, e.g., using a visible spectra spectrophotometer.
- Ex vivo gene therapy refers to the isolation of cells from an animal or patient, the delivery of a nucleic acid into the cells in vitro, and then the return of the modified cells back into an animal or individual. This may involve the surgical removal of tissue/organs from an animal or patient or the primary culture of cells and tissues.
- APC can be prepared from PBMC isolated by density centrifugation of whole blood.
- Human mononuclear cells (MNC) prepared from bone marrow also can be used as APC.
- Bone marrow can be obtained from the tibiae, femora, spine, ribs, hips, sternum, as well as the humeri, radi, ulna, tibiae, and fibulae. Additionally, these cells also can be obtained from cord blood, peripheral blood, or cytokine-mobilized peripheral blood.
- Other sources of human hematopoietic stem cells include embryonic yolk sac, fetal liver, fetal and adult spleen, and blood.
- the marrow layer is centrifuged over a density gradient to produce a pellet of red cells at the bottom of the tube, a clear layer of media, an interface layer which contains the MNC and a plasma medium layer on top.
- the interface layer may then be removed using, for example, suction. Centrifugation of this layer at 1 OOOg ultimately yields a MNC pellet.
- This pellet may then be resuspended in a suitable buffer for cell sorting by FACS.
- the isolated MNC can be cultured in vitro to expand the immunologically active cells.
- the expanded, therapeutically active cells are then loaded with peptide and provided to the patient to obtain a therapeutic effect.
- APC also can be dendritic cells, generated from bone marrow or peripheral blood. Fibroblasts can serve as APC, and then can be cultured from tissues such as the skin.
- mice DBA/2 mice were bred and housed in a pathogen-free facility. Female mice 8-10 weeks of age were used for studies.
- P815 mastocytoma cells were cultured in DMEM o supplemented with 10% FCS and incubated at 37 C in a 8% CO2 atmosphere.
- Pl.HTR a highly transferable variant of P815
- PI a tumorigenic clone of P815
- PI 98 a turn " clone of P815; P511, an azaguanine-resistant variant of P815; and
- P1204 a P815AB-negative variant carrying a deletion of gene P1A (Uyttenhove et al. 1983).
- P815.B7-1 and P198.B7-1 cells were obtained by electroporation respectively of PI and P198 cells with the B7-1 cDNA cloned by PCRTM into plasmid pcDSR ⁇ and with the plasmid pRc/RSV (Invitrogen, San Diego, CA) conferring neomycin resistance.
- L1210 is a leukemia cell line derived from a DBA/2 mouse, which was cultured under the same conditions as P815 cells.
- L1210 transfectants expressing antigen P815AB were generated by co-electroporation of the C1A.3.1 cosmid (Gajewski et al., 1995) with plasmid pSVtkneob conferring neomycin resistance.
- L1210.P1A.B71 cells were obtained by transfection of L1210.P1A cells with the murine B7-1 cDNA cloned into plasmid pEFBOS (Gajewski et al., 1995) (containing a puromycin resistance gene) by electroporation, and selection with puromycin and limiting dilution cloning. All transfectants were maintained in selection drug at least every second passage; for in vivo injections the cells were always cultured in the absence of the selection drug.
- CTL Pl :5 a clone specific for antigen P815A, and the P198.3 CTL clone specific for P198, were cultivated in 1 ml cultures containing 5x10 irradiated DBA/2 spleen cells and 10 5 irradiated (10,000 rad) PI cells (for clone Pl :5) or P198 cells (for clone P198.3) as stimulators.
- cultures contained 50% of supernatant from secondary mixed lymphocyte culture (MLC) as a source of cytokines.
- MLC secondary mixed lymphocyte culture
- Tumor peptides Peptides were synthesized and purified by reverse phase HPLC and characterized by amino acid analysis using standard techniques.
- the single letter code sequences of the peptides used are as follows: H-2K d -restricted P198, KYQAVTTTL (SEQ ID NO:l), and
- rmIL-12 As source of rmIL-12, initial studies were performed using a hexahistidine-tagged IL-12 fusion protein expressed in and purified from transfected mammalian cells, as described (Fallarino et al, 1996). All the principal studies were repeated using highly purified rmIL- 12.
- Splenocytes obtained from naive DBA/2 female mice were used as a source to prepare the following antigen presenting cells (APCs):
- DC Dendritic cells
- Unfractionated splenocytes Pools of DBA/2 splenocytes were washed twice in medium containing 0.5% NMS then counted and incubated with the specific tumor peptide and used in in vivo or in vitro studies.
- LPS blasts In this case spleen cell suspensions (10 x 10 /ml) were cultured for 48 hours at 37°C in 10 cm tissue culture dishes in medium containing 0.5% NMS in the presence of LPS (25 ⁇ g/ml). Living cells were then harvested washed 3 times to remove excess of LPS. FACS analysis with an anti-B220 mAb and anti-IgM showed approximately 80% of the cells were activated B cells.
- Splenocytes were washed twice in medium containing 0.5% NMS and allowed to adhere for two hours at 37 C; non-adherent cells were removed and washed twice and incubated for 30 min. at 4°C with anti-Thy-1 and anti-MAC-1 (M170) mAb. After washing, the antibody-bounded cells were lysed by treatment with rabbit complement at 37 °C for 30 min. The cells were washed again and the remaining cells were recovered after sedimentation over Ficoll-Hypaque. Greater than 98%) of the recovered cells were B cells based on FACS analysis with anti-B220 and anti-IgM antibodies.
- PBMC Peripheral blood mononuclear cells
- FACS analysis 1 x IO 6 cells in 100 ⁇ l of FACS buffer (PBS containing 3% FCS and 0.02%) sodium azide) were stained in v-bottom microtiter plates with FITC-conjugated mAbs specific for MHC-class I (30-5-7S), I-A d (MKD6), B7-1 (16-10A1), B7-2 (GL1), CDl lc
- MLTC Mixed lymphocyte-tumor culture
- Stimulation of peripheral blood lymphocytes was performed by mixing 3 x 10 Ficoll-purified PBMC with 10 irradiated stimulating cells (10,000 rad) and 2 x 10 irradiated (2000 rad) normal syngeneic spleen cells 1 ml per well of 48-well plates. CTL activity was assessed after 6-7 days.
- Chromium-release assay Effector cells were diluted in duplicate in v-bottom microtiter plates and mixed with 2000 Cr-labeled target cells in a final volume of 200 ⁇ l of complete medium. In some studies, 10 cold competitor cells were mixed with the labeled target cells before addition to the effector cells. Supematants were collected after incubation for 4 hours at 37°C and radioactivity was measured using a 96-well plate counter (Packard Instmments). The percentage of 51 Cr-specific release was calculated as described.
- mice were challenged by s.c. injection in the left flank with 1 x 10° Pl .HTR tumor cells in 100 ⁇ l of DPBS. The size of the tumors was assessed twice per week by measuring the largest and smallest diameters. Data are reported as the average of the tumor diameters at each time point. All studies included five mice per group and were repeated at least twice.
- P198-peptide pulsed spleen-derived dendritic cells are recognized by a P198-specific CTL clone but are unable to prime efficiently a P198-specific T cell response in vivo.
- vaccination strategies employing peptide-pulsed dendritic cells were explored in the P815 murine tumor model.
- Several tumor antigen genes have been cloned from P815 and its "turn " " variants, and the specific antigenic peptides recognized by CTL have been characterized.
- the K -restricted antigen PI 98 and the L -restricted antigen PI A were studied in detail.
- Dendritic cells were purified from DBA spleen using the adherence/de-adherence method first described by Steinman (Steinman et al, 1979) .
- DC isolated in this way were >90% N418 + and expressed high levels of B7-1, B7-2, and class I and II MHC molecules (FIG. 1). They also were very effective at stimulating in a primary allogeneic mixed-lymphocyte reaction.
- sDC To assess the ability of sDC to present functional peptide/MHC complexes on the cell surface, they were pulsed with various doses of the PI 98 peptide and then cultured in the presence of the specific CTL clone CTL P198.6.
- sDC pulsed with the specific P198 peptide stimulated the secretion of TNF by CTL P198.6 in a dose-dependent fashion, at concentrations as low as 0.1 nM (FIG. 2). Plateau stimulation occurred at approximately 100 nM of peptide.
- sDC incubated in the absence of PI 98 peptide or in the absence of the CTL clone did not result in specific cytokine production (FIG. 2).
- sDC pulsed with PI 98 peptide were next used to immunized syngeneic DBA mice in vivo.
- Naive DBA 2 mice were inoculated weekly for three consecutive weeks with 5 x 10 sDC that had been pulsed in vitro with 1 ⁇ M PI 98 peptide. This concentration was chosen to ensure that the plateau levels of stimulation observed with the CTL clone in vitro could be maintained in vivo, but to avoid too high a peptide concentration that might preferentially generate T cells with low-affinity TCRs.
- Pulsed cells were injected either i.v., i.p., or intra-footpad (f.p.); control groups were injected with PBS or with sDC incubated only in PBS during the peptide pulsing period.
- the general scheme for the immunization schedule is depicted in FIG. 3.
- mice immunized with P198-pulsed sDC in combination with rmIL-12 CTL responses in mice immunized with P198-pulsed sDC in combination with rmIL-12. Because the importance of IL-12 during rejection of immunogenic P815 tumor variants in vivo was demonstrated previously (Fallarino et al., 1996), and because of the ability of this cytokine to promote a lytic Thl/Tcl phenotype, exogenous rmIL-12 was administered along with the P198-pulsed sDC during the immunization protocol. All subsequent immunizations were performed via the footpad route. Naive DBA/2 mice were immunized weekly for three consecutive weeks with sDC pulsed with 1 ⁇ M PI 98 peptide as before.
- rmIL-12 (10 ng per footpad per day), was injected in the same sites on the day of immunization and on the subsequent two days (FIG. 3).
- Control mice received sDC incubated with no peptide, sDC plus rmIL-12, or just PBS.
- co-administration of rmIL-12 along with the peptide-pulsed sDC generated specific anti-P198 cytolytic activity in 100%) of the mice while injection of P198 peptide-pulsed sDC did not elicit specific CTL activity.
- the ability to detect specific CTL was not improved by using P198.B7-1 cells to stimulate in the MLTC.
- mice (6 per group) were immunized with 5 x 10 ⁇ sDC pulsed with 1 ⁇ M PI 98 peptide as indicated in FIG. 3.
- rmIL-12 was injected either on day 0 only, or on days 0, 1, and 2 of each immunization. Cytolytic activity was analyzed 2 weeks after the third immunization using either spleen cells (column 1) or PBMC (column 2) as a source of responding cells. Mice were considered to be positive if the specific lysis at an E:T ratio of 100:1 was greater than 25 and if the difference between lysis of PI 98 and P511 was greater than 15.
- the ability of IL-12 to augment the ability of pulsed sDC to immunize in vivo prompted examination of other sources of APC that might be simpler to obtain, thus being easier to apply to human immunization protocols. It was also desirable to examine cell types that normally are poor APC or even tolerogenic when used alone. The inventors' reasoning was that provision of IL-12 might make any class I + cell capable of initiating a CTL response upon re-injection in vivo.
- FIG. 1 shows the level of expression of class I and class II MHC molecules on these cell populations, as well as the levels of costimulatory molecules B7-1 or B7-2.
- Non-fractionated splenocytes and PBMC were examined first, compared to sDC. In these studies, each APC population was pulsed with an equal concentration of the PI 98 peptide (1 ⁇ M), but mice were injected with varying numbers of the pepti de-loaded APCs. The results in FIG.
- each APC type was pulsed with increasing concentrations of PI 98 peptide, irradiated and washed, and cultured with the CTL clone PI 98.6. IFN- ⁇ content was tested after 48 hours in the supematants. As shown in FIG. 6, each APC type was capable of stimulating the CTL clone PI 98.6. However, it was clear that a higher peptide concentration was needed when using splenocytes, PBMC or resting B cells compared to sDC in order to obtain a comparable response.
- mice were immunized with various numbers of PI 98 peptide-pulsed
- non-DC APC B cells, splenocytes, or PBMC along with rmIL-12 on days 0, 1, and 2 as before.
- the non-DC APC were loaded with 10 ⁇ M peptide whereas the sDC were loaded with 1 ⁇ M peptide prior to immunization.
- comparable levels of CTL activity were induced on a per-cell basis when 10-fold greater peptide concentration was used for the pulsing of non-DC APC populations.
- purified B cells effectively immunized argues against the possibility that contaminating DC in the APC populations are responsible for the actual priming.
- the relative inefficiency of non-DC as APC to immunize in vivo could be overcome either by increasing the number of pulsed cells or by increasing the concentration of the peptide used for pulsing.
- PI A presented by L ⁇ was chosen.
- PI A is a good model antigen because the PI A gene, like the MAGE gene family in human tumors (De Plaen et al, 1994), is expressed in several murine mastocytoma cell lines, but is silent in adult tissues except for the testis and placenta (Uyttenhove et al, 1997).
- mice Two weeks after the last immunization, all the mice were tested for specific anti-P815A CTL activity in the peripheral blood following a 6 day MLTC. Also in this case the 2 different stimulator cells were used for the in vitro MLTC. The first was the syngeneic tumor L1210 transfected to express the gene PI A (L1210.P1A), and the second was L1210.P1A.B71 cell line, a double transfectant expressing PI A and B7-1. Lytic activity was tested against P815, which expresses antigen P815A, and on the negative control cell line P1204, a P815 variant that had lost the expression of gene P1A (Uyttenhove et al, 1983).
- Pl.HTR is a highly transfectable variant of P815 that expresses the P815A epitope and grows as a solid tumor in vivo, growing progressively in about 90% of naive syngeneic DBA/2 mice (Gajewski et al, 1996).
- the results in FIG. 9 show that mice immunized with P815A-pulsed PBMC plus rmIL-12 not only acquired specific anti-P815A CTL but also were protected against challenge with a tumor expressing the same antigen.
- mice did not reject the PlA-negative variant of P815, P1204, demonstrating antigen specificity.
- mice injected with PBMC loaded with P815A peptide but not given rmIL-12 or with empty PBMC and rmIL-12 were not protected against tumor challenge (FIG. 9).
- a good correlation was evident between the ability of peptide-pulsed PBMC plus IL-12 to induce CTL activity and to protect against a tumor challenge.
- immunization with peptide-loaded PBMC in the absence of IL-12 failed to induce protective immunity in vivo just as it was unable to facilitate the generation of specific anti-tumor CTL.
- Dendritic cells are prepared by culturing fresh splenocytes on tissue culture dishes for 1.5 h, rinsing away the non-adherent cells, and culturing overnight at 37°C in culture medium. The non-adherent cells are isolated by gentle rinsing; these are predominantly dendritic cells (Inaba et al, 1987). B cells are purified by removal of adherent cells, depletion of T cells with anti-Thy-1 mAb and complement, and Percoll density centrifugation (Stack et al, 1994).
- mice In vivo tumor studies in mice.
- 2-10 x 10 peptide-pulsed APC of various sorts are prepared in a volume of 50 ⁇ l DPBS. They are injected via a 1 cc syringe through a 23 gauge needle. Locations to inject include subcutaneously in the hind footpads or flanks, or intravenously through the tail vein. Inoculation with living tumor cells is usually performed subcutaneously on the flank.
- Pl.HTR and the other P815 variants 5 x 10 cells has been used to generate tumor growth in the majority of mice. Tumor size is measured in the largest and shortest dimensions, and a mean is calculated for each data point. Every effort is made to minimize discomfort to the animals.
- Cytolysis assay Cytolysis is measured using a Cr-release assay. Effector cells are collected, counted, and resuspended at a concentration of 2 x 10 6 /ml. Targets to be assayed are loaded with Na 2 51 CrO 4 , washed, and resuspended at 2 x 10 5 /ml. Serial dilutions of effector cells are made in V-bottom microtiter plates in a volume of 100 ⁇ l, and an equal volume of labeled targets is added. For cold target inhibition, a 20- to 50-fold excess of unlabeled targets is added per well.
- the plate is briefly centrifuged, incubated at 37°C for 4-5 hours, and 'Cr-release is measured from supematants using a 96-well plate gamma counter. Spontaneous release is measured from target cells alone, and maximal release is measured from target cells lysed with Triton X-100. Percent maximal Cr -release is calculated as described (Lancki et al. , 1987).
- Cytokine assays by ELISA Several cytokines are assayed by standard ELISA techniques. The principal cytokines examined are IFN- ⁇ , TNF- ⁇ , IL-2, and IL-4. Briefly, 96- well plates are coated with the relevant anti-cytokine mAb, washed, and blocked with a protein- containing buffer to prevent non-specific binding. They are washed, and serial dilutions of the test supematants or a standard (usually a recombinant version of the cytokine) are prepared in duplicate. After incubating and washing again, a second anti-cytokine Ab is added and the plates are incubated.
- the plates After washing, the plates are developed using a horseradish peroxidase-coupled third Ab followed by a substrate that generates a colored product.
- the plates are read on an ELISA reader, and the half-maximal dilutions are compared to the standard and converted to pg/ml or U/ml.
- PCRTM for MAGE-3 or Melan-A gene expression PCRTM analysis of tumor samples for expression of the MAGE-3 or Melan-A genes are performed as part of the clinical immunization protocol using techniques well known to those of skill in the art. Briefly, messenger RNA (mRNA) from frozen or fresh tumor samples is isolated using the guanidine/cesium chloride method. cDNA are synthesized using oligo(dT) 15 as a primer according to standard methods.
- mRNA messenger RNA
- cDNA are synthesized using oligo(dT) 15 as a primer according to standard methods.
- RT-PCRTM analysis of tumor samples for expression of the MAGE-3 and Melan-A genes is performed using the following oligonucleotides and program.
- the oligonucleotide primers to be used for MAGE-3 PCRTM are:
- oligonucleotide primers to be used for Melan-A PCRTM are:
- the oligonucleotide primers to be used for ⁇ -actin control are:
- Antisense 5'-GCTGGAAGGTGGACAGCGA-3' (SEQ IS NO:8).
- PCRTM is performed for 40 cycles at an annealing temperature of 58°C. PCRTM products are visualized using 1.5% EtBr-stained agarose gels. The expected size of the PCRTM products are 725 bp for MAGE-3, 605 bp for Melan-A, and 615 bp for ⁇ -actin. No attempt at quantitation is made. For cases in which very small amounts of tissue are available (e. g. a CT-guided core biopsy), a second round of nested PCRTM is performed with a set of primers internal to the first as described in Example 6.
- HLA typing HLA typing for class I MHC only is performed by using standard methods well known to the skilled artisan.
- Peripheral blood (approximately 100-150 cc) is collected with heparin from each patient prior to each scheduled immunization, and three weeks after the final immunization.
- the cells are diluted 2:1 in DPBS, placed over a Ficoll-Hypaque or Lymphoprep gradient, and centrifuged at 3000 rpm for 15 minutes at room temperature.
- the mononuclear cells are collected from the interface, washed with DPBS, and counted. They then are prepared for the vaccine or for cryopreservation as indicated in the clinical protocol.
- This example outlines a general protocol for a non-randomized study of immunization with Mage3 or MelanA peptide-pulsed autologous PBMC plus escalating doses of rhIL-12 in selected patients with metastatic melanoma.
- the protocol consists of immunization with a mixture containing the patient's own blood cells with a peptide of Mage3 or MelanA, depending on which the patient's own cancer cells are producing. Varying doses of recombinant human interleukin-12 (rhIL-12) are also given.
- Mage3 and MelanA are proteins produced by the majority of melanoma tumors examined.
- Cancer cells producing one of these proteins break it down into smaller peptide fragments which stick to the surface of the cell via HLA antigens.
- Cytotoxic T lymphocytes CTL
- the design of the protocol in this example is to stimulate the body to produce CTL that will specifically kill tumor cells.
- Patient therapy is initially consists of 3 cycles. Each treatment cycle is 21 days in length, consisting of immunization (peptide-pulsed PBMC) and rhIL-12 injection on the first day, rhIL-12 injection on the third and fifth day, and a 16 day rest period.
- An initial cohort of 3-6 patients receives the MAGE-3- or Melan-A-pulsed PBMC alone. No placebo in place of rhIL-12 is given. If a patient has an objective response or stable disease, therapy may continue for additional sets of 3 cycles.
- Dose Escalation Dose of rhIL-12 are escalated in cohorts of >3 patients unless a dose limiting toxicity (DLT) is encountered. If DLT occurs in one of the first 3 patients at a dose level, then three additional patients are treated at that dose level to determine if the maximally tolerated dose (MTD) has been exceeded. If none of the first three patients at a dose level experience DLT after 2 cycles, then dose escalation may proceed to the next level.
- the MTD is defined as the dose level at which at least 2 of 3 or 2 of 6 patients experience DLT.
- the recommended phase II dose is one dose level below the MTD, or the dose that gives optimal immunization as measured by T cell responses, whichever is lower. In the unlikely scenario that a DLT is seen only with one peptide and not the other, then immunization with that peptide is explored further as an independent cohort.
- Inclusion criteria comprises:
- HLA typing patient must express HLA-A2.
- MAGE-3 or Melan-A expression tumor must express MAGE-3 or Melan-A by RT- PCRTM analysis.
- Exclusion criteria comprises:
- CT scans will be done as necessary for tumor staging and until PD is documented. Approximately 10 ml of clotted blood will be collected for serum storage. An aliquot of PBMC prepared on day 1 of each cycle will be cryopreserved for future assessment of CTL. Following-up will be life-long. DTH for PPD and recall antigens will be performed again when therapy is complete.
- the MAGE-3 and Melan-A peptides are produced according to GMP standards by Multiple Peptide Systems, San Diego, CA.
- the following MAGE-3 peptide (using single letter amino acid designations) is used for patients expressing HLA-A2 and with MAGE-3 + tumors: FLWGPRALV (SEQ ID NO: 9)
- the following Melan-A peptide is used for patients expressing HLA-A2 and with Melan-A + tumors: AAGIGILTV (SEQ ID NO: 10)
- Each peptide is provided in lyophilized vials containing 1 g each.
- a single vial of MAGE-3 peptide is reconstituted at a concentration of 20 ⁇ M in Dulbecco's PBS (DPBS; Gibco/BRL), stored in 5 ml aliquots at -80°C.
- the Melan-A peptide is reconstituted in DMSO, then diluted in DPBS. This volume is added to an equal volume of autologous PBMC for incubation (pepti de-pulsing) at the time of preparing each vaccine.
- rhIL-12 is manufactured and provided by the Genetics Institute (Cambridge, MA).
- the rhIL-12 drug product is supplied as a lyophilized powder in 5 ml vials under mild vacuum. Each vial contains 50 ⁇ g of rhIL- 12. Vials are intended for single use only.
- Sterile water for injection (WFI) is supplied to reconstitute the product. Bacteriostatic WFI should not be used.
- the lyophilized rhIL-12 must be stored in a secured refrigerated facility at 2-8°C. The WFI may be stored at room temperature. After reconstitution, doses are stable for 2 h at 2-8°C. Unit doses prepared in a syringe may be kept at room temperature and must be used within 4 h of preparation. Lyophilized rhIL-12 is reconstituted with either 5 or 1 ml of sterile WFI. Reconstitution is complete in approximately 1 minute.
- the patient is admitted for the first immunization and rhIL-12 injection.
- PBMC peripheral blood sample
- peripheral blood sample Approximately 100-150 ml of peripheral blood is collected using standard phlebotomy technique, directly into 2-3 60cc syringes containing 0.6 cc preservative-free heparin. An aliquot of the peripheral blood sample
- PBMC is isolated by centrifugation over a Lymphoprep gradient (Gibco/BRL), counted, washed in DPBS, and resuspended in DPBS at a concentration of 40 x 10 cells/ml.
- An equal volume of the relevant peptide solution (prepared at 20 ⁇ M in DPBS) is added, and the suspension is incubated for 1 h at 37°C with gentle rocking.
- the cells are then lethally irradiated (2000 cGy), washed once with DPBS, and resuspended in DPBS at a concentration of 50 x 10 in 0.5 ml.
- the suspension of peptide-loaded PBMC is injected subcutaneously using a 1 cc syringe and 21 g needle, divided evenly into 2 sites.
- the preferred sites of injection are near draining lymph node locations but not near a tumor mass. Examples of appropriate sites would be the proximal thigh, the upper arm, or the lower abdominal wall.
- rhIL-12 at the dose level assigned to the patient is injected subcutaneously using a 3cc syringe and 25g needle as soon as possible after pulsed PBMC inoculation, immediately adjacent to 1 of the 2 immunization sites. If the patient is to receive the vaccination alone without rhlL- 12, then no placebo injection is given. The appearance of each injection site is recorded just before, 1 h after, and 24 h after immunization. In some instances, photographs are taken with a metric mler in view to document inflammation.
- Blood samples (10 cc in a red top Vaccutainer tube) are taken just before, then 12 h, 24 h, and 6 days after immunization. Semm are isolated and stored at -20°C for subsequent measurement of cytokine levels.
- rhIL-12 (if assigned to the patient) is injected subcutaneously in approximately the same location as the first injection on days 3 and 5 as an outpatient.
- Assays will be performed to measure peptide-specific CTL activity and cytokine levels once a practical number of samples have been collected.
- Capillary leak syndrome (At least 1 of the following): acute weight gain > 10% orthostatic hypotension on at least 2 occasions new pleural effusions drop in blood pressure requiring pressors without obvious cause pulmonary edema without obvious cause Dose-limiting (withdraw)
- Toxicities greater than grade 3 or satisfying numbers 6, 7, or 8 from the above table are reported as adverse experiences to the FDA and to the Genetics Institute. In the unlikely circumstance that unusual or dose-limiting toxicities are observed with only the MAGE-3 or the Melan-A peptide, then treatment with that peptide is explored as an independent cohort.
- Symptomatic care may be given as required with medications such as antiemetics and analgesics.
- medications such as antiemetics and analgesics.
- administration of corticosteroids requires that the patient be removed from the study.
- An event is defined as any change in the physiologic or psychologic state other than the primary condition that qualifies the patient for the study.
- Patients are evaluated at least every 2 wk (usually day 1 and day 7 of a cycle) while receiving treatment, every 8 wk until there is evidence of tumor progression, then at 8-12 wk intervals so long as the patient is able to return. Patients are observed for 1 h after each rhIL-12 injection to monitor for immediate toxicity.
- Tumor masses are characterized carefully with bidimensional measurements.
- Criteria for a Partial Response 50% reduction in the sum of the product of the largest perpendicular diameters of the indicator lesions identified prior to therapy.
- Criteria for a Complete Response total disappearance of all evidence of tumor without appearance of new lesions.
- Criteria for Progressive Disease appearance of new lesions; and/or fifty percent increase in the sum of the product of the largest perpendicular diameters of the indicator lesions.
- This cutoff has been chosen because initial increases in tumor size followed by tumor shrinkage have been observed in the first MAGE-3 peptide immunization experience; and/or reappearance of any tumor.
- SD Criteria for Stable Disease
- Patients meeting the criteria for a PR or SD may be retreated for additional courses of 3 cycles. Patients with a CR may be treated with I additional course of 3 cycles and then treatment ceases.
- HLA typing is performed using standard methods.
- Serum levels of IFN- ⁇ and TNF- ⁇ are assessed by standard ELISA technique.
- CD8 + PBL are isolated using magnetic beads.
- the CD8 population is pulsed with the relevant MAGE-3 or Melan-A peptide, irradiated (2000 cGy), and added as stimulator cells along with IL-2. After 1 wk the responding cells are restimulated again in the same fashion. After another wk, cytolytic activity is measured by chromium-release against a peptide-pulsed B cell line expressing HLA-A2 (T2 cells). Negative controls include non-pulsed T2 cells and the NK- sensitive target K562. Cold competition may be performed with unlabeled K562 cells to eliminate non-specific NK activity.
- Descriptive statistics are generated to describe the frequency of observed toxicities and immunologic changes induced by each of the small dose cohorts.
- phase II dose there are sufficient numbers of patients (13-16) studied to allow more formal statistical inferences to be made.
- Immunologic responses before treatment are compared to those following each immunization using paired t-tests. Varying baselines are expected between patients, so a log transformation is employed and 95% confidence intervals generated for the mean ratio between post-treatment and baseline responses.
- the baseline values and each of the post-immunization results are analyzed using repeated measures analysis of variance to determine the pattern of response over multiple treatment cycles.
- Biopsy of tumor is a required part of this protocol in order to examine expression of the MAGE- 3 or Melan-A genes by RT- PCRTM. Standard histology are performed to verify the pathologic diagnosis of the specimen.
- This example provides results for patients immunized with PBMC incubated with Mage3 peptide or MelanA peptide plus assigned doses of rhIL-12 ranging from 0-100 ng/kg. Patients were treated with peptide-pulsed PBMC alone, using either Mage3 or MelanA peptide as indicated, or with rhIL-12 administered subcutaneously near the immunization site. Following immunization, assays for peptide specific CTL activity and cytokine production, in particular IFN- ⁇ were conducted. Data for clinical responses are also presented. Abbreviations, definitions and methods have been previously set forth in Example 3.
- Example 3 General inclusion criteria have been set for in Example 3. Additional criteria are as follows: 1. KPS 0-1 , intact organ function to receive rhIL-12, HLA-A2-positive; multiple prior therapies allowed, life expectancy 12 wk. 2. Tumor biopsied or obtained surgically, and expression of Mage3 and MelanA assessed by RT-PCRTM. Nested PCRTM done for small biopsy material. Only antigen-expressing patients allowed. Priority given to Mage3.
- PBMC peripheral blood mononuclear cells
- Mage3 peptide 10 ⁇ M
- MelanA peptide 50 ⁇ M
- Peptide concentrations were chosen based on lowest optimal dose for stabilization of HLA-A2 expression on T2 cells.
- Pulsed PBMC were irradiated (2000 rad), centrifuged, and resuspended in 2cc DPBS for injection.
- Injection of pulsed PBMC was performed subcutaneously, divided between 2 sites, either in upper arms or proximal legs.
- rhIL-12 at the assigned dose level (ng/kg), was injected subcutaneously near one of the two vaccine sites.
- T cell functional analysis was performed in batch fashion, with all samples from a given patient thawed and restimulated in vitro simultaneously.
- Vaccination of melanoma patients with refractory metastatic disease was demonstrated using tumor antigen peptide-pulsed autologous PBMC plus rhIL-12. This approach is faster and easier than dendritic cell expansion.
- Recoupling was performed with three equivalents of amino acids and DIC for those coupling steps that indicated a positive Ninhydrin test result. These include Phe and Leu . As a
- the formyl protecting group on the tryptophan residue was removed using a 20% piperidine/DMF solution. As a precaution, this step was performed twice to ensure the removal of the protecting group. Final yield of the resin was 61.6 grams corresponding to 92% of theoretical yield.
- the cmde peptide was analyzed by HPLC and the purity was determined to be ⁇ 63%. Under the conditions described, the peptide eluted at ⁇ 9 min.
- the peptide was purified using Reverse Phase High Performance Liquid Chromatography (HPLC), with CIs resin as the stationary phase.
- HPLC Reverse Phase High Performance Liquid Chromatography
- a single step purification using TFA as the buffer resulted in the desired purity. This resulted in the TFA salt of the purified peptide.
- a total of 9.8 g of pure peptide, TFA salt was obtained from purification of 20 g of cmde peptide, a yield of 49%. All 13 lots were prepared for exchange to the acetate, salt. As an in- process check, samples from each lot were pooled together, 1 mg for every 417 rag, dissolved in 90%) HOAc/Milli Q water at 5 mg/ mL and analyzed by HPLC. The purity of this "mini-pool" was -99%. Each purification lot was individually dissolved in 10% HOAc/WFL.
- the peptide was eluted from the column with 3 column volumes of 10% HOAc/WFL
- The-peptide solution was shell frozen in 1200 mL Virtis lyophilization flasks and lyophilized to dryness on a Virtis FM25EL lyophilizer for -66 hours.
- the product was weighed and resulted in a yield of 8.2 grams of peptide acetate salt, 91% of theoretical value.
- the product was packaged in low density polyethylene containers with polypropylene closures, blanketed with argon and sealed with parafilm. Two containers of 1 g were labeled according to RMS 300043 Rev. 0-a. (See Attachment 2 for labeling information).
- the product was released for distribution after the batch records had been reviewed and approved by QC, and the product had been tested and found to meet specifications.
- the peptide was shipped on dry ice.
- N-Boc-L-V aline Merrifield Resin N-Boc-L-Arginine (tosyl), N-Boc-L-Leucine H 2 0, N-Boc-L-Alanine, N-Boc-Glycine, N-Boc -L-Tryptophan (formyl), N- Boc-Phenylalanine, and N-Boc-L-Proline.
- Tumor samples are obtained in the OR, radiology suite, or clinic and placed into sterile isotonic solution (PBS or Isotonic saline) on ice and brought directly to the lab. All the information about the patients (name, MR#, tumor site) is written in the tumor log book.
- PBS sterile isotonic solution
- guanidine homogenate to extract RNA; freeze some vials in liquid nitrogen and keeping a record of it in the freezer log book; homogenyze some in a solution of Hyaluronidase (85 U/ml) and Collagenase (lU/ml) in DMEM to grow cell lines and possibly clone.
- the tumor is left in the hyalurondase/collagenase until as much of the tumor has separated into a cell suspension as possible (usually a few hours are needed). If the tumor is too big it is cut into smaller pieces using sterile instmments and technique, always keeping the tumor sample on ice.
- guanidine homogenate (use RNAase free reagents and keep samples on ice as much as possible), weigh the tissue which is to be homogenized in guanidine. Add the guanidine solution directly to the sample. If sample ⁇ 50mg, add 0.5cc of guanidine. If sample >50mg, add 3.2cc of guanidine. Homogenize sample, on ice, using the electric homogenizer (powergen 125; Fisher). Use disposable sterile generators for each separate tumor sample. Always clean homogenizer with SDS % and ethanol 70% for each sample. Homogenize samples until as much of solid tumor has been homogenized as possible. Centrifuge the homogenate at 3,000 rpm for 10 min at 4°C. Aspirate supernatant which can now be stored at - 70°C for long-term storage.
- RNA extraction carefully load the guanidine lysate onto the top of the CsCl solution. If original sample was ⁇ 50mg, then use 0.8cc ultraclear centrifuge tubes (Beckman). Note that there is 0.5cc guanidine lysate/.17cc CsCI. If original sample was >50mg, then use 5ml ultraclear centrifuge tubes (Beckman) and use 3.2cc guanidine/l.lcc CsCI. Ultracentrifuge at 35,000 rpm for 18 h at 20°C in SW 50.1 rotor (overnight) ⁇ maximal acceleration and no brake. After ultracentrifugation remove most of supernatant by hand pipette (RNA pellets at bottom of tube and is often not visible). Place tubes upside down in an appropriate carrier to drain any remaining liquid.
- RNAase-free water lOO ⁇ l
- Eppendorf tube On ice, appropriately labeled. Rinse the cup with an additional lOO ⁇ l of RNAase-free water and add it to the Eppendorf tube.
- RNAase-free water Dissolve RNA in 7 ⁇ l RNAase-free water by gentle pipetting. Quantitate yield using Invitrogen DNA dipstick method. Add 1 ⁇ l RNAasin to each sample. The sample may be stored at -70°C at this stage.
- RNAase For removal of contaminating DNA from RNA preparation (using Gibco amplification grade DNAase), add the following to a small microcentrifuge tube on ice: up to 1 ⁇ g RNA per ⁇ g DNAase to clean-up reaction; 1 ⁇ l of 10X DNAase buffer (Gibco); 1 ⁇ l DNAase amplification grade (Gibco); and RNAase free water to bring volume up to 10 ⁇ l. Incubate sample at room temperature for 15 min. Add 1 ⁇ l of 25mM EDTA (Gibco) and heat at 65 °C in water bath for 10 min. The sample is ready for cDNA synthesis.
- RNAasin 40U/ul; Promega
- Reverse Transcriptase 200U/ul; Gibco
- Eppendorfs In separately labeled Eppendorfs add 1 ⁇ l of Oligo dT primer (0.5ug/ ⁇ l) and add 10 ⁇ l of each RNA sample into the appropriately labeled tube. Add 9 ⁇ l of master mix (from above) to each sample. Vortex and place into water bath at 37°C for 1 h. Add 30 ⁇ l of sterile water to each sample after incubation and place in -20°C freezer in appropriately labeled box.
- Nested PCRTM reactions are done using the same above PCRTM conditions and for 40 cycles.
- the product from the primary PCRTM reaction is diluted 1 :10 by adding 2 ⁇ l of the primary PCRTM product to 18 ⁇ l of sterile water. 2 ⁇ l of this dilution is then used for the nested reaction.
- Primers are all reconstituted in 1ml of sterile water on arrival and then diluted to a concentration of about lOO ⁇ g/ml prior to use.
- Primary primer templates are as follows:
- B-actin (5' primer) GGCATCGTGATGGACTCCG (SEQ ID NO:l 1);
- B-actin (3' primer) GCTGGAAGGTGGACAGCGA (SEQ ID NO:12);
- MAGE-1 (5' primer) CGGCCGAAGGAACCTGACCCAG (SEQ ID NO:13);
- MAGE-1 (3' primer) GCTCCGACCCTCACTGGGTTGCC (SEQ ID NO:14); MAGE-3 (5' primer) TGGAGGACCAGAGGCCCCC (SEQ ID NO: 15);
- MAGE-3 (3' primer) GGACGATTATCAGGAGGCCTGC (SEQ ID NO: 16);
- Tyrosinase (5' primer) GGATAGCGGATGCCTCTCAAAG (SEQ ID NO: 17);
- Tyrosinase (3' primer) CCCAAGGAGCCATGACCAGAT (SEQ ID NO: 18);
- Nested primer templates are as follows:
- MAGE-1 (5' primer) CTTCAGGTTTTCAGGGGACAGGCC (SEQ ID NO:21); MAGE-1 (3' primer) CTGTCGAGTGAAGTTGATGGTAGTGG (SEQ ID NO:22); MAGE-3 (5' primer) TCACATGCTCCCTCTCTCCCCAGGCC (SEQ ID NO:23); MAGE-3 (3 'primer) ATCTGATTGTCACCCAGCAGGCCATC (SEQ ID NO:24);
- Tyrosinase (5' primer) GCATGCACAATGCCTTGCACATCTATA (SEQ ID NO:25); Tyrosinase (3' primer) TGTAGTCTTGAAAAGAGTCTGGGTCTG (SEQ ID NO:26); Melan-A (5' primer) TCTTACACCACGGCTGAAGAGGCC (SEQ ID NO:27); and Melan-A (3' primer) CCTCACATGATTAGTGCTAGCGGA (SEQ ID NO:28). All PCRTM products are run on 1.5% agarose gels with ethidium bromide. Sizes of tumor antigen bands for primary PCRTM are shown below:
- compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
- Trinchieri "Interleukin 12 induces stable priming for interferon gamma (IFN- ⁇ ) production during differentiation of human T helper (Th) cells and transient IFN- ⁇ production in established Th2 clones," J. Exp. Med, 179:1273, 1994.
- IFN- ⁇ interferon gamma
- Van den Eynde "The expression of mouse gene PI A in testis does not prevent safe induction of cytolytic T cells against a PlA-encoded tumor antigen.” Int. J. Cancer. 70:349-356, 1997.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU38659/99A AU767208B2 (en) | 1998-04-23 | 1999-04-23 | Combination of antigen pulsed APCS and interleukin 12 for tumor and viral therapy |
NZ507829A NZ507829A (en) | 1998-04-23 | 1999-04-23 | Vaccine adjuvants for immunotherapy of melanoma |
EP99921452A EP1071450A2 (en) | 1998-04-23 | 1999-04-23 | Combination of antigen pulsed apcs and interleukin 12 for tumour and viral therapy |
CA002326406A CA2326406A1 (en) | 1998-04-23 | 1999-04-23 | Combination of antigen pulsed apcs and interleukin 12 for tumor and viral therapy |
JP2000544352A JP2002512202A (en) | 1998-04-23 | 1999-04-23 | Vaccine adjuvant for immunotherapy of melanoma |
AU2004200444A AU2004200444A1 (en) | 1998-04-23 | 2004-02-06 | Vaccine adjuvants for immunotherapy of melanoma |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/064,964 US6080399A (en) | 1998-04-23 | 1998-04-23 | Vaccine adjuvants for immunotherapy of melanoma |
US09/168,832 | 1998-10-08 | ||
US09/064,964 | 1998-10-08 | ||
US09/168,832 US6716422B1 (en) | 1998-04-23 | 1998-10-08 | Vaccine adjuvants for immunotherapy of melanoma |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1999053949A2 true WO1999053949A2 (en) | 1999-10-28 |
WO1999053949A3 WO1999053949A3 (en) | 2000-03-09 |
WO1999053949A9 WO1999053949A9 (en) | 2000-05-25 |
Family
ID=26745085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/008889 WO1999053949A2 (en) | 1998-04-23 | 1999-04-23 | Combination of antigen pulsed apcs and interleukin 12 for tumor and viral therapy |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1071450A2 (en) |
JP (1) | JP2002512202A (en) |
AU (1) | AU767208B2 (en) |
CA (1) | CA2326406A1 (en) |
NZ (1) | NZ507829A (en) |
WO (1) | WO1999053949A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000071709A1 (en) * | 1999-05-21 | 2000-11-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Polypeptides, vesicular carriers of glutamate and gaba |
WO2001056599A2 (en) * | 2000-02-04 | 2001-08-09 | Triad Immunologies, Llc | Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors |
WO2004069272A2 (en) * | 2003-02-05 | 2004-08-19 | Movecare Ltd | Adjuvant combination for use in the immunization of a mamal comprising il2 and il12 |
WO2007071390A1 (en) * | 2005-12-21 | 2007-06-28 | Sentoclone Ab | Method for treating malignant melanoma |
US8101173B2 (en) | 2005-12-21 | 2012-01-24 | Sentoclone International Ab | Method for treating urinary bladder cancer |
US8206702B2 (en) | 2005-12-21 | 2012-06-26 | Sentoclone International Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer |
US8211425B2 (en) | 2005-12-21 | 2012-07-03 | Sentoclone International Ab | Method for treating disseminated cancer |
US8709404B2 (en) | 2002-10-11 | 2014-04-29 | Sentoclone International Ab | Immunotherapy in cancer treatment |
WO2019136305A1 (en) * | 2018-01-04 | 2019-07-11 | Neumedicines Inc. | Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009133863A1 (en) * | 2008-04-28 | 2009-11-05 | 国立大学法人浜松医科大学 | Immunopotentiating agent comprising ep1 agonist |
WO2009145303A1 (en) * | 2008-05-29 | 2009-12-03 | シスメックス株式会社 | PRIMER FOR DETECTION OF TYROSINASE mRNA |
JP2012025694A (en) * | 2010-07-23 | 2012-02-09 | Asahi Kasei Kuraray Medical Co Ltd | Cancer therapeutic agent |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997022349A1 (en) * | 1995-12-20 | 1997-06-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for in vivo t cell activation by antigen-pulsed dendritic cells |
-
1999
- 1999-04-23 JP JP2000544352A patent/JP2002512202A/en not_active Withdrawn
- 1999-04-23 AU AU38659/99A patent/AU767208B2/en not_active Ceased
- 1999-04-23 EP EP99921452A patent/EP1071450A2/en not_active Withdrawn
- 1999-04-23 WO PCT/US1999/008889 patent/WO1999053949A2/en not_active Application Discontinuation
- 1999-04-23 CA CA002326406A patent/CA2326406A1/en not_active Abandoned
- 1999-04-23 NZ NZ507829A patent/NZ507829A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997022349A1 (en) * | 1995-12-20 | 1997-06-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for in vivo t cell activation by antigen-pulsed dendritic cells |
Non-Patent Citations (5)
Title |
---|
BHARDWAJ N. ET AL: "IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro" THE JOURNAL OF CLINICAL INVESTIGATION, vol. 98, no. 3, 1996, pages 715-722, XP002127215 * |
FALLARINO, F. ET AL: "Coadministration of IL - 12 obviates the need to use dendritic cells in tumor antigen peptide-pulsed antigen-presenting cell (APC) vaccination." FASEB JOURNAL, (MARCH 20, 1998) VOL. 12, NO. 5, PP. A908. MEETING INFO.: ANNUAL MEETING OF THE PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY 98, PART II SAN FRANCISCO, CALIFORNIA, USA APRIL 18-22, 1998, XP002127214 * |
MUKHERJI B. ET AL: "Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 92, 1995, pages 8078-8082, XP002127216 cited in the application * |
TUTING T ET AL: "Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha" JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 160, no. 3, page 1139-1147 XP002102051 ISSN: 0022-1767 * |
ZITVOGEL L. ET AL: "IL-12 engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo" ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 795, 1996, pages 284-293, XP000867039 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000071709A1 (en) * | 1999-05-21 | 2000-11-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Polypeptides, vesicular carriers of glutamate and gaba |
WO2001056599A2 (en) * | 2000-02-04 | 2001-08-09 | Triad Immunologies, Llc | Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors |
WO2001056599A3 (en) * | 2000-02-04 | 2002-03-07 | Triad Immunologies Llc | Hyperthermia and immunotherapy for leukemias, lymphomas, and solid tumors |
US8709404B2 (en) | 2002-10-11 | 2014-04-29 | Sentoclone International Ab | Immunotherapy in cancer treatment |
WO2004069272A2 (en) * | 2003-02-05 | 2004-08-19 | Movecare Ltd | Adjuvant combination for use in the immunization of a mamal comprising il2 and il12 |
WO2004069272A3 (en) * | 2003-02-05 | 2004-11-25 | Movecare Ltd | Adjuvant combination for use in the immunization of a mamal comprising il2 and il12 |
WO2007071390A1 (en) * | 2005-12-21 | 2007-06-28 | Sentoclone Ab | Method for treating malignant melanoma |
US8101173B2 (en) | 2005-12-21 | 2012-01-24 | Sentoclone International Ab | Method for treating urinary bladder cancer |
US8206702B2 (en) | 2005-12-21 | 2012-06-26 | Sentoclone International Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer |
US8211425B2 (en) | 2005-12-21 | 2012-07-03 | Sentoclone International Ab | Method for treating disseminated cancer |
US8211424B2 (en) | 2005-12-21 | 2012-07-03 | Sentoclone International Ab | Method for treating malignant melanoma |
WO2019136305A1 (en) * | 2018-01-04 | 2019-07-11 | Neumedicines Inc. | Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
WO1999053949A9 (en) | 2000-05-25 |
CA2326406A1 (en) | 1999-10-28 |
EP1071450A2 (en) | 2001-01-31 |
AU767208B2 (en) | 2003-11-06 |
NZ507829A (en) | 2004-03-26 |
AU3865999A (en) | 1999-11-08 |
JP2002512202A (en) | 2002-04-23 |
WO1999053949A3 (en) | 2000-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6716422B1 (en) | Vaccine adjuvants for immunotherapy of melanoma | |
KR101216655B1 (en) | PROTEINS BELONGING TO THE Bcl-2 FAMILY AND FRAGMENTS THEREOF, AND THEIR USE IN CANCER PATIENTS | |
EP1012240B1 (en) | Cancer immunotherapy with semi-allogeneic cells | |
US20070071722A1 (en) | Nucleotide vaccine composition | |
US20060045881A1 (en) | Anti-cancer vaccines | |
KR100603075B1 (en) | Use of mhc class ? ligands as adjuvant for vaccination and of lag-3 in cancer treatment | |
JP6682438B2 (en) | Improved cell compositions and methods for cancer treatment | |
CA3026572A1 (en) | Calr and jak2 vaccine compositions | |
SA519410007B1 (en) | Peptides and methods for the treatment of diabetes | |
WO1999053949A2 (en) | Combination of antigen pulsed apcs and interleukin 12 for tumor and viral therapy | |
EP1670899A2 (en) | Vaccines for cancer, autoimmune disease and infections | |
JP2007507521A (en) | In vivo efficacy of NY-ESO-1 and adjuvant | |
US20060045883A1 (en) | Anti-cancer vaccines | |
WO2020145222A1 (en) | Novel neoantigens and cancer immunotherapy using same | |
US20060045884A1 (en) | Vaccines for autoimmune and infectious disease | |
MXPA00010378A (en) | Vaccine adjuvants for immunotherapy of melanoma | |
Koide et al. | Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70 | |
US20150202273A1 (en) | Prostate-specific tumor antigens and uses thereof | |
AU2004200444A1 (en) | Vaccine adjuvants for immunotherapy of melanoma | |
CN112402596A (en) | Polypeptide composition and vaccine | |
Micallef | The Development of Effective Tumour Vaccines | |
André et al. | Session 05: Presentation of tumour antigens | |
Immunotherapy | Divergent Roles for CD4 | |
MXPA99012024A (en) | Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-83, DESCRIPTION, REPLACED BY NEW PAGES 1-91; PAGES 84-87, CLAIMS, REPLACED BY NEW PAGES 92-95; PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; PAGES 1-8, SEQUENCE LISTING, REPLACED BY NEW PAGES 1-7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
ENP | Entry into the national phase |
Ref document number: 2326406 Country of ref document: CA Ref country code: CA Ref document number: 2326406 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 2000 544352 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/010378 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 38659/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 507829 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999921452 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999921452 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 38659/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999921452 Country of ref document: EP |